Investment House LLC Sells 16 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Investment House LLC trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 699 shares of the biopharmaceutical company’s stock after selling 16 shares during the quarter. Investment House LLC’s holdings in Regeneron Pharmaceuticals were worth $614,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Eudaimonia Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 1.2% during the fourth quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock worth $803,000 after acquiring an additional 11 shares during the period. Drive Wealth Management LLC increased its holdings in Regeneron Pharmaceuticals by 4.0% during the 4th quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 12 shares during the period. MCF Advisors LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 12 shares during the period. Sutton Wealth Advisors Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 38.2% in the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 13 shares during the period. Finally, Clearview Wealth Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 1.5% during the 4th quarter. Clearview Wealth Advisors LLC now owns 855 shares of the biopharmaceutical company’s stock worth $751,000 after buying an additional 13 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $892.48 on Tuesday. The stock has a market cap of $97.96 billion, a P/E ratio of 25.68, a P/E/G ratio of 2.54 and a beta of 0.11. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The firm has a fifty day moving average price of $946.89 and a 200 day moving average price of $894.83. Regeneron Pharmaceuticals, Inc. has a 1 year low of $684.80 and a 1 year high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. The company had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. Regeneron Pharmaceuticals’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the prior year, the business posted $10.96 earnings per share. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current year.

Wall Street Analyst Weigh In

REGN has been the subject of a number of research reports. Truist Financial reaffirmed a “buy” rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Bank of America increased their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. BMO Capital Markets lifted their price target on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a report on Monday, February 5th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, April 15th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $977.77.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the transaction, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the sale, the executive vice president now owns 13,789 shares of the company’s stock, valued at $12,888,716.19. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,195 shares of company stock worth $9,759,898. 8.83% of the stock is owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.